FDAnews

TARGEGEN REPORTS PRECLINICAL DATA FOR TG100801

TargeGen has reported that in preclinical studies, topical administration of the prodrug, TG100801 significantly reduced vascular endothelial growth factor (VEGF) mediated retinal leakage and choroidal neovascularization in models of macular degeneration.

In cell-based assays, following topical instillation, TG100572 was shown to induce apoptosis in proliferating endothelial cells responsible for neovasculariztion and to inhibit inflammatory-mediated processes as measured by endotoxin-induced nitric oxide release in vitro. These attributes suggest that TG100801 may be effective in treating several major back of the eye diseases in humans.